65,437 trials
Chronic Periodontitis
Primary: Frequency of Blood Dendritic Cells From Baseline — 12; 14 % MFI
Chronic Hip Joint Pain · Prearthritic Hip Disease
Primary: Percentage of Participants Who Are Adherent to Treatment Attendance — 21; 22 Participants — p=1.0
Metabolic Syndrome
Primary: Number of PP-MI-Based Health Behavior Intervention Exercises Completed — 7.0 Exercises completed
Glioma
Primary: Progression-free Survival
Chronic Kidney Disease
Primary: Change in Subjective Units of Distress Scale (SUDS) Score — 2.92; 3.12 score on a scale
Cataract · Astigmatism
Primary: Percentage of Eyes With Absolute Value of Intraocular (IOL) Rotation (Visit 00 to Visit 4) — 99.1; 0.9; 100.0; 0.0 percentage of eyes
Breast Cancer
Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL
Actinic Keratosis
Primary: Primary Efficacy Outcome Measure — 50; 49; 8 Participants — p=<0.0001
CD19+ Diffuse Large B-cell Lymphomas · Follicular Lymphomas · Mantle Cell Lymphomas
Primary: Dose-limiting Toxicity — 8.33 percentage of subjects
Quality of Life · Self Efficacy · Knowledge
Primary: Change in Oral Health Related Quality of Life (OHIP-14; Slade, 1997) — 16.8; 12.4; 10.5 score on a scale — p=.000
Youth · Homelessness
Primary: Mean Change From Baseline in Hopelessness as Measured by the Beck Hopelessness Scale — NA; 6.70; NA; 4.27 score on a scale — p=0.428
Quality Improvement
Primary: Hospital Admissions Per Person Year Alive Measured at the Facility Month Level — 5.5; 5.8 hospitalizations per person year alive — p=<.05
PTSD
Primary: Change in PTSD Checklist (PCL-5) — -13.1; -8.9; -13.8; -7.5 units on a scale — p=0.15
Multiple Myeloma
Primary: Percentage of Participants With Progression-free Survival (PFS) — 47.7; 44.1; 45.0 percentage of participants — p=0.60
Psychology, Social · Adolescent Behavior
Primary: Time Spent Holding Gun — 29.57; 21.14; 82.86; 48.62 Seconds